by Clinical Neuropsychologist | Thursday, November 21, 2024 | Dementia
Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...
by Clinical Neuropsychologist | Wednesday, November 20, 2024 | Dementia
Abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate...
by Clinical Neuropsychologist | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Patterns of signal from tau positron emission tomography (tau-PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer’s disease (AD) research if they are linked to differential biomarker...
by Clinical Neuropsychologist | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Progression to Alzheimer’s disease (AD) dementia from normal cognition (NC) can follow different trajectories, with most progressing through a recognizable mild cognitive impairment stage (NC–MCI–AD), while some individuals transition...
by Clinical Neuropsychologist | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Neighborhood environments may promote neurocognitive health in part by providing amenities that encourage physical activity. We examined associations between quantity of walkable facilities, including specifically physical activity facilities...
